首页|静脉铁剂在妇科异常子宫出血缺铁性贫血患者中的合理应用评价

静脉铁剂在妇科异常子宫出血缺铁性贫血患者中的合理应用评价

扫码查看
目的 了解妇科异常子宫出血缺铁性贫血(AUD-IDA)患者静脉铁剂应用情况,建立药物利用评价(DUE)标准,并采用层次分析法(AHP)综合评价静脉铁剂临床应用的合理性,为临床合理用药提供参考。方法 收集安徽理工大学第一附属医院2022 年 1 月至 12 月应用静脉铁剂治疗AUD-IDA患者的病历资料,从蔗糖铁注射液的适应症、给药途径及频次、日剂量、溶媒、联合用药、禁忌症等方面进行专项合理性点评,制定该药DUE标准。采用AHP对 2022 年 1 月至 12 月妇科 113 例应用静脉铁剂的归档病例进行分析评价。结果 使用蔗糖铁注射液患者 113 例,适应证、给药途径、溶媒、禁忌症、过敏反应处理均合理;存在的不合理之处主要为:给药频次不适宜、日剂量不适宜、联合用药不适宜、总补铁量不达标以及用药后未进行持续性用药监护。各病例分值 90~100 分、70~<90 分、60~<70 分的患者及其占比分别为 6 例(5。31%)、106例(93。81%)和 1 例(0。88%)。结论 AUD-IDA患者在临床应用静脉铁剂时应注意用法用量、总补铁量、药物的联合应用以及用药后的持续性用药监护,提高其使用合理性。
Evaluation of rational use of intravenous iron in patients with iron deficient anemia and abnormal uterine bleeding in gynaecology
Objective To investigate the application of intravenous iron in patients with abnormal uterine bleeding(AUD)and iron deficiency anemia(IDA)in gynecology,to establish the drug utilization evaluation(DUE)standard,and to comprehensively evaluate the rationality of the clinical application of intravenous iron by analytic hierarchy process(AHP),so as to provide reference for the rational use of intravenous iron in clinical practice.Methods The medical records of patients with AUD and IDA from January to December 2022 in the First Affiliated Hospital of Anhui University of Science and Technology were collected,and the special rationality of the drug was evaluated from the aspects of indications,route and frequency of administration,daily dosage,solvent,combination medication,and contraindications of iron sucrose injection,and the DUE standard of the drug was formulated.AHP was used to analyze and evaluate 113 archived cases of intravenous iron in gynecology from January to December 2022.Results A total of 113 patients were treated with iron sucrose injection,and the indications,route of administration,solvent,contraindications,and allergic reactions were reasonable.The main unreasonableness was that the frequency of administration was inappropriate,the daily dose was inappropriate,the combination was not appropriate,the total iron supplement was not up to standard,and there was no continuous drug monitoring after medication.The case scores 90~100,70~<90 and 60~<70 were 6(5.31%),106(93.81%)and 1(0.88%),respectively.Conclusion Patients with AUD and IDA should pay attention to the dosage,total amount of iron supplementation,combined application of drugs and continuous medication monitoring after intravenous iron supplementation,so as to improve the rationality of their use.

Drug utilization evaluation standardAnalytic hierarchy processAbnormal uterine bleedingIron deficiency anemiaIron sucrose injectionEvaluation standard

徐静、张华、李凡、李茗薇、王晓娟

展开 >

安徽理工大学第一附属医院(淮南市第一人民医院)药学部(安徽淮南 232007)

安徽理工大学第一附属医院(淮南市第一人民医院)妇产科(安徽淮南 232007)

药物利用评价标准 层次分析法 异常子宫出血 缺铁性贫血 蔗糖铁注射液 评价标准

安徽省高等学校科学研究项目淮南市指导性科技计划项目

2022AH0508032022159

2024

中国药师
国家药品监督管理局高级研修学院,武汉医药(集团)股份有限公司

中国药师

CSTPCD
影响因子:0.944
ISSN:1008-049X
年,卷(期):2024.27(2)
  • 20